Use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies

Bookmark and Share
Published: 10 Jul 2019
Views: 173
Rating:
Save
Dr Elizabeth Pease - AstraZeneca, UK

Dr Elizabeth Pease speaks to ecancer at the WIN 2019 Symposium in Paris about the use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies.

She explains that by combining drugs the hope is that responses are deeper and more durable.

Dr Pease explains that developing these combinations is tricky and that it is important to look into the dosing, schedule and application to the right patient populations in order to maximise the benefit.